Keyword Connections

multiple myeloma

Journals

13

1 transplant infectious disease : an official journal of the transplantation society

2 Cells

3 rna biology

4 Haematologica

5 advances in experimental medicine and biology

6 british journal of nursing (mark allen publishing)

7 Nature structural & molecular biology

8 zhonghua nei ke za zhi

9 Leukemia research

10 Transplantation proceedings

11 Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

12 the physician and sportsmedicine

13 European journal of haematology

Research Groups

0

No Research Group Connected

Bibliographies

117

1 Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling.

2 Exertional Rhabdomyolysis and Causes of Elevation of Creatine kinase.

3 A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone.

4 Knowledge and Attitudes of Students of the Rzeszow University About the Transplantation of Organs.

5 Patients' experiences of living with multiple myeloma.

6 CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.

7 FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of FANCD2 during DNA repair.

8 Roneparstat: Development, Preclinical and Clinical Studies.

9 light chain myeloma induced severe hypertriglyceridemia

10 bet inhibitors in the treatment of hematologic malignancies: current insights and future prospects

11 crescentic glomerulonephritis in iga multiple myeloma: a case report

12 ultrasound-guided emergency pericardiocentesis of a patient with multiple myeloma in a resource limited setting

13 multiple myeloma cells express key immunoregulatory cytokines and modulate the monocyte migratory response

14 infections in hospitalised patients with multiple myeloma: main characteristics and risk factors

15 celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma

16 polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mtor/p70s6k pathway

17 prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma

18 neuroblastoma in a 55-year-old patient: a case report

19 the non-coding rna landscape of plasma cell dyscrasias

20 proteolytic activity of human lymphoid tumor cells.correlation with tumor progression

21 anti-multiple myeloma drug-associated taste dysfunction: an analysis of the faers database

22 early application of high cut-off haemodyalisis for de-novo myeloma nephropathy is associated with long-term dialysis-independency and renal recovery

23 primary biliary cirrhosis and igg-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship?

24 dendritic cell therapies for hematologic malignancies

25 bortezomib modulates chit1 and ykl40 in monocyte-derived osteoclast and in myeloma cells

26 carfilzomib boosted combination therapy for relapsed multiple myeloma

27 a case of internal carotid artery thrombosis associated with thalidomide administration in multiple myeloma

28 plasma cell leukemia presenting as a chest wall mass: a case report

29 myeloid derived suppressor cells as therapeutic target in hematological malignancies

30 an unusual presentation of pseudomonas aeruginosa blebitis following combined surgery

31 development and validation of an algorithm to identify patients with multiple myeloma using administrative claims data

32 high serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment

33 mieloma múltiplo: 50 casos diagnosticados por citometria de fluxo multiple myeloma: 50 cases diagnosed by flow cytometry

34 targeted dna vaccines for enhanced induction of idiotype (id)-specific b and t cells

35 medical image of the week: headcheese sign

36 treatment of multiple myeloma at clinical department of hematology, university medical centre ljubljana with autologous hematopoietic stem cell transplantation in years 2014 and 2015

37 treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis

38 management of multiple myeloma and usage of bortezomib: perspective from india and ukraine

39 single-dose anti-cd138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model

40 metastatic pulmonary calcinosis and leukocytoclastic vasculitis in a patient with multiple myeloma

41 partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy

42 detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma

43 immunophenotype of normal and myelomatous plasma cell subsets

44 Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

45 Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

46 The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

47 Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential.

48 The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

49 Targeting multiple myeloma with natural polyphenols.

50 Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence?

51 Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient

52 The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

53 CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

54 A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

55 Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.

56 Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.

57 Outcomes of autologous transplantation for multiple myeloma according to different induction regimens

58 Is regular laryngoscopy necessary for multiple myeloma patients? Case report and review of literature

59 Acute gouty arthritis and rapidly progressive renal failure as manifestation of multiple myeloma: clinical case description

60 Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

61 2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway

62 Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial.

63 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

64 Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature.

65 CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy

66 Mass Cytometry Discovers Two Discrete Subsets of CD39−Treg Which Discriminate MGUS From Multiple Myeloma

67 Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.

68 High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.

69 International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

70 Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

71 Progressive multifocal leucoencephalopathy associated with multiple myeloma

72 (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

73 Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

74 Hyperphosphatemia in multiple myeloma

75 Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma.

76 Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

77 Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

78 concurrent presentation of hodgkin lymphoma and multiple myeloma

79 evodiamine selectively inhibits multiple myeloma cell growth by triggering activation of intrinsic apoptosis pathway

80 circulating cd3+cd4+cd161+ cells are associated with early complications after autologous stem cell transplantation in multiple myeloma

81 immunological dysregulation in multiple myeloma microenvironment

82 targeting ongoing dna damage in multiple myeloma: effects of dna damage response inhibitors on plasma cell survival

83 mieloma múltiplo neste fascículo multiple myeloma in this issue

84 oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature

85 effectiveness of treatment of an elderly patient with good prognosis of multiple myeloma

86 concomitant occurrence of multiple myeloma with diffuse large b-cell lymphoma

87 inhibition of p-selectin and psgl-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib

88 massive retroperitoneal hemorrhage as an initial presentation of a rare and aggressive form of multiple myeloma

89 lung postmortem autopsy revealing extramedullary involvement in multiple myeloma causing acute respiratory distress syndrome

90 pulmonary-renal syndrome as a clinical expression of multiple myeloma

91 brain abscesses caused by nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

92 a 54-year-old woman with donor cell origin of multiple myeloma after allogeneic hematopoietic stem cell transplantation for the treatment of cml

93 inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma

94 hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?

95 tratamento do mieloma múltiplo recidivado relapsed multiple myeloma treatment

96 serum parathyroid hormone is a new potential risk factor in multiple myeloma

97 cytodiagnosis of multiple myeloma presenting as chest wall swellings

98 smoldering multiple myeloma

99 systemic mastocytosis with smoldering multiple myeloma: report of a case

100 transferrin-conjugated snalps encapsulating 2′-o-methylated mir-34a for the treatment of multiple myeloma

101 incb16562, a jak1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support